AMERICAN INTERNATIONAL GROUP, INC. - PROTAGONIST THERAPEUTICS INC ownership

PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 145 filers reported holding PROTAGONIST THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.11 and the average weighting 0.3%.

Quarter-by-quarter ownership
AMERICAN INTERNATIONAL GROUP, INC. ownership history of PROTAGONIST THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$475,463
-34.0%
28,505
+9.2%
0.00%
-25.0%
Q2 2023$720,716
+39.5%
26,094
+16.2%
0.00%
+33.3%
Q1 2023$516,488
+115.1%
22,456
+2.0%
0.00%
+50.0%
Q4 2022$240,118
+30.5%
22,009
+0.8%
0.00%
+100.0%
Q3 2022$184,000
+8.2%
21,845
+1.4%
0.00%0.0%
Q2 2022$170,000
-67.7%
21,537
-3.0%
0.00%
-66.7%
Q1 2022$526,000
-35.3%
22,210
-6.6%
0.00%
-25.0%
Q4 2021$813,000
+87.3%
23,772
-2.9%
0.00%
+100.0%
Q3 2021$434,000
-58.3%
24,483
+5.7%
0.00%
-50.0%
Q2 2021$1,040,000
+95.5%
23,165
+12.9%
0.00%
+100.0%
Q1 2021$532,000
+44.2%
20,527
+12.2%
0.00%
+100.0%
Q4 2020$369,000
+4.2%
18,303
+1.0%
0.00%
-50.0%
Q3 2020$354,000
+45.1%
18,115
+31.2%
0.00%
+100.0%
Q2 2020$244,000
+229.7%
13,809
+32.3%
0.00%
Q1 2020$74,000
-5.1%
10,439
-5.5%
0.00%
Q4 2019$78,000
-39.5%
11,041
+2.7%
0.00%
-100.0%
Q3 2019$129,000
+10.3%
10,755
+11.5%
0.00%
Q2 2019$117,000
+85.7%
9,642
+32.4%
0.00%
Q1 2018$63,000
-60.6%
7,285
-5.1%
0.00%
-100.0%
Q4 2017$160,000
+44.1%
7,677
+22.1%
0.00%
Q3 2017$111,000
+68.2%
6,288
+8.1%
0.00%
Q2 2017$66,000
+13.8%
5,818
+27.5%
0.00%
Q1 2017$58,0004,5640.00%
Other shareholders
PROTAGONIST THERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
JOHNSON & JOHNSON 2,449,183$56,331,20918.32%
Kynam Capital Management, LP 1,375,000$31,625,0004.08%
BVF INC/IL 3,775,900$86,845,7003.18%
Cormorant Asset Management, LP 1,700,000$39,1002.58%
RTW INVESTMENTS, LP 4,600,799$105,818,3772.20%
Ghost Tree Capital, LLC 225,000$5,175,0001.53%
683 Capital Management, LLC 791,000$18,193,0001.36%
Ikarian Capital, LLC 211,400$4,862,2001.10%
Ikarian Capital, LLC 211,400$4,862,2001.10%
SILVERARC CAPITAL MANAGEMENT, LLC 105,486$2,426,1781.00%
View complete list of PROTAGONIST THERAPEUTICS INC shareholders